Does Eagle Pharma (NASDAQ:EGRX) Look Attractive Now? Mizuho Initiates Coverage


Why Has Mizuho Given Eagle Pharma (NASDAQ:EGRX) a $112 Price Target

New York: Eagle Pharma (NASDAQ:EGRX) coverage has been initiated with a key ‘”Buy”‘ rating as well as a $112 target price per share at Mizuho. The target price by Mizuho could mean upside of 11.77% from the last stock close.

Approximately 57 shares of stock traded hands. Eagle Pharmaceuticals Inc (NASDAQ:EGRX) has risen 76.30% since May 6, 2015 and is uptrending. It has outperformed by 77.10% the S&P500.

Analysts await Eagle Pharmaceuticals Inc (NASDAQ:EGRX) to reports earnings on December, 16. They expect $-0.54 EPS, up 16.92% or $0.11 from last year’s $-0.65 per share. After $-0.53 actual EPS reported by Eagle Pharmaceuticals Inc for the previous quarter, Wall Street now forecasts 1.89% negative EPS growth.

Eagle Pharmaceuticals, Inc. is a specialty pharmaceutical company. The company has a market cap of $1.56 billion. The Firm focused on developing and commercializing injectable products. It currently has negative earnings. It develops products that address the shortcomings, as identified by physicians, pharmacists and other stakeholders, of existing commercially injectable products.

According to Zacks Investment Research, “Eagle Pharmaceuticals, Inc. is a specialty pharmaceutical company. It focuses on developing and commercializing injectable products primarily in the critical care and oncology areas in the United States. The Company markets EP-1101 to treat heparin-induced thrombocytopenia. It develops EP-3101, EP-3102, Ryanodex and EP-4104. Eagle Pharmaceuticals, Inc. is based in Woodcliff Lake, New Jersey.” Get a free copy of the Zacks research report on Eagle Pharmaceuticals Inc (EGRX).